Skip to main content
Graduate School of Biomedical Sciences

Recent Publications from the Greenblatt Lab

Greenblatt DJ 2019. Public health risk of designer psychotropic drugs: Should PHASE be phased in? Clin Pharmacol Ther. doi: 10.1002/cpt.1578. Abstract

Enimil A, Antwi S, Yang H, Dompreh A, Alghamdi WA, Gillani FS, Orstin A, Bosomtwe D, Opoku T, Norman J, Wiesner L, Langaee T, Peloquin CA, Court MH, Greenblatt DJ, Kwara A. 2019. Effect of first-line antituberculosis therapy on nevirapine pharmacokinetics in children younger than 3 years old. Antimicrob Agents Chemother. Epub ahead of print. Abstract

Kharasch ED, Greenblatt DJ. 2019. Methadone disposition: Implementing lessons learned. J Clin Pharmacol. 59: 1044-1048. Abstract

Uchimura T, Nakamura DS, Link EM, Noguchi Y, Ōmura S, Sunazuka T, Greenblatt DJ, Zeng L. 2019. Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity. Biochem Pharmacol. 165: 79-90. Abstract

Nozari A, Akeju O, Mirzakhani H, Eskandar E, Ma Z, Hossain MA, Wang Q, Greenblatt DJ, Martyn JAJ. 2019. Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. J Pharm Pharmacol. 71: 982-987. Abstract

Greenblatt HK, Greenblatt DJ. 2019. Designer benzodiazepines: A review of published data and public health significance. Clin Pharmacol Drg Dev. 8: 266-269. Abstract

Greenblatt DJ, Mikus G. 2019. Ketoconazole and liver injury: A five-year update. Clin Pharmacol Drug Dev. 8: 6-8. Abstract

Matin B, Sherbini AA, Alam N, Harmatz JS, Greenblatt DJ. 2019. Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid. Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid. J Pharm Pharmacol. 71: 371-378. Abstract

Fiaturi N, Greenblatt DJ. 2019. Therapeutic drug monitoring of antidepressants. Handb Exp Pharmacol. 250: 545-546. Abstract

Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ. 2018. Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old. Antimicrob Agents Chemother. 63(1). pii: e01657-18  Abstract

Chow CR, Harmatz JS, Ryan MJ, Greenblatt DJ. 2018. Persistence of a posaconazole-mediated drug-drug interaction with ranolazine after cessation of posaconazole administration: Impact of obesity and implications for patient safety. J Clin Pharmaco. 58: 1436-1442 Abstract

Greenblatt HK, Greenblatt DJ. 2018. Gabapentin and pregabalin for the treatment of anxiety disorders. Clin Pharmacol Drug Dev. 7: 228-232. Abstract

Algeelani S, Alkhelb D, Greenblatt DJ. 2018. Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on in-vitro metabolism of canagliflozin in human liver microsomes. Biopharm Drug Dispos. 39: 135-142. Abstract

Greenblatt DJ. 2018. Opioid prescribing: What are the numbers? Clin Pharmacol Drug Dev. 7: 6-8. Abstract

Johnson-Agbakwu C, Brown L, Yuan J, Kissling R, Greenblatt DJ. 2018. Effects of flibanserin on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy premenopausal women: A randomized crossover study. Clin Ther. 40: 64-73. Abstract

Greenblatt DJ, Harmatz JS, Shader RI. 2018. Update on Psychotropic Drug Prescribing in the United States: 2014-2015. J Clin Psychopharmaol. 38: 1-4. Abstract

Greenblatt DJ, Patel M, Harmatz JS, Nicholson WT, Rubino CM, Chow CR. 2017. Impaired rivaroxaban clearance in mild renal insufficiency With verapamil coadministration: Potential implications for bleeding risk and dose selection. J Clin Pharmacol. 58: 533-540. Abstract

Alam N, Angeli MG, Greenblatt DJ.. 2017. Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir. J Pharm Pharmcol. 69: 1794-1801.  Abstract

Hossain MA, Tran T, Chen T, Mikus G, Greenblatt DJ 2017. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J Pharm Pharmacol. 69: 1786-1793. Abstract

Algeelani S, Alam N, Hossain MA, Mikus G, Greenblatt DJ. 2017. In vitro inhibition of human UGT isoforms by ritonavir and cobicistat. Xenobiotica 11: 1-6. Abstract

Cao L, Kwara A, Greenblatt DJ. 2017. Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 69: 1762-1772. Abstract

Court MH, Zhu Z, Masse G, Duan SX, James LP, Harmatz JS, Greenblatt DJ. 2017. Race, gender, and genetic polymorphism contribute to variability in acetaminophen pharmacokinetics, metabolism, and protein-adduct concentrations in healthy African-American and European-American volunteers. J Pharmacol Exp Ther. 362: 431-440. Abstract

Cao L, Greenblatt DJ, Kwara A. 2017. Inhibitory effects of selected antituberculosis drugs on common human hepatic cytochrome P450 and UDP-glucuronosyltransferase enzymes. Drug Metab Dispos. 45: 1035-1043. Abstract

Greenblatt D. 2017. Mechanisms and consequences of drug-drug interactions. Clin Pharmacol Drug Dev. 6: 118-124. Abstract

Schaller SJ, Alam SM, Mao J, Zhao Y, Blobner M, Greenblatt DJ, Martyn JA. 2017. Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. J Pharm Pharmacol. 69: 82-88. Abstract

Greenblatt HK, Greenblatt DJ. 2016. Antidepressant-associated hyponatremia in the elderly. J Clin Psychopharmacol. 36: 545-549.  Abstract

Ng I, Greenblatt HK, Greenblatt DJ. 2016. Stereo-Psychopharmacology: The case of citalopram and escitalopram. Clin Pharmacol Drug Dev. 5: 331-335.  Abstract

Greenblatt DJ. 2016. Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies. J Clin Pharmacol. 56: 152-156.  Abstract

Elliott KR, Harmatz JS, Zhao Y, Greenblatt DJ. 2016. Body size changes among national collegiate athletic association New England Division III football players, 1956-2014: Comparison With Age-Matched Population Controls. J Athl Train. 51: 373-381.  Abstract

Greenblatt DJ. 2016. Clinical pharmacology in drug development - an update. Clin Pharm Drug Dev. 4: 243-244.  Abstract

Greenblatt HK, Greenblatt DJ. 2016. Meldonium (mildronate): A performance-enhancing drug? Clin Pharm Drug Dev. 5: 167-169. Abstract

Greenblatt, DJ. 2016. A soft benzodiazepine. Clin Pharm Drug Dev. 4: 81-82.  Abstract

Greenblatt DJ, Abourjaily PN. 2016. Pharmacokinetics and pharmacodynamics for medical students:A proposed course outline. J Clin Pharmacol. 56: 1180-1195.  Abstract

Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, Cudkowicz ME.2015. Preclinical rodent toxicity studies for long term use of ceftriaxone. Toxicol Rep. 2:1396-1403  Abstract

Qian Y, Sherbini A, Matin B, Zhao Y, Castellot J, Greenblatt DJ. 2015. Inhibition of 2-methoxyestradiol glucuronidation by probenecid. J Pharm Pharmacol. 67: 1585-1592.  Abstract

Greenblatt DJ. 2015. The pharmacovigilance syndrome. J Clin Psychopharmacol. 35: 361-363. Abstract

Greenblatt DJ, Harmatz JS. 2015. Ritonavir is the best alternative to ketoconazole as index inhibitor of Cytochrome P450-3A in drug-drug interaction studies. Brit J Clin Pharmacol. 80: 242-250. Abstract

Zhao Y, Harmatz JS, Epstein CR, Nakagawa Y, Kurosaki C, Nakamura T, Kadota T, Giesing D, Court MH, Greenblatt DJ. 2015. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br J Clin Pharmacol. 80: 1076-1085. Abstract

Greenblatt HK, Greenblatt DJ. 2015. Altered drug disposition following bariatric surgery: A research challenge. Clin Pharmacokinet. 54: 573-579. Abstract

 

Epstein LC, Masse G, Harmatz JS, Scott TM, Papas AS, Greenblatt DJ. 2014. Characterization of cognitive dysfunction in Sjögren's syndrome patients. Clin Rheumatol. 33: 511-521. Abstract